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Outcomes After Implantation of the
TAXUS Paclitaxel-Eluting Stent in Saphenous
Vein Graft Lesions
Results From the ARRIVE (TAXUS Peri-Approval Registry:
A Multicenter Safety Surveillance) Program
Emmanouil S. Brilakis, MD, PHD,* John M. Lasala, MD, PHD,† David A. Cox, MD,‡
Peter B. Berger, MD,§ Thomas S. Bowman, MD, MPH,储 Ruth M. Starzyk, PHD,储
Keith D. Dawkins, MD储
Dallas, Texas; St. Louis, Missouri; Allentown and Danville, Pennsylvania;
and Natick, Massachusetts
Objectives The aim of this study was to examine the incidence of clinical events after implantation
of the TAXUS Express (Boston Scientiﬁc Corporation, Natick, Massachusetts) paclitaxel-eluting stent
in saphenous vein graft (SVG) lesions in an unselected patient population.
Background Saphenous vein grafts have 1-year occlusion rates of 12% to 20%, with ⬎50% failure by 7
to 10 years. Many diseased SVGs are treated by percutaneous coronary intervention to avoid higher-risk
reoperation, but bare-metal stents have 35% to 40% historical SVG restenosis rates by 18 months. Reported outcomes of drug-eluting stents in SVG lesions are limited and mainly retrospective.
Methods The ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program
compiled data on 7,492 patients receiving ⱖ1 TAXUS Express (Boston Scientiﬁc) stent, including 474
patients with SVG. All cardiac events were monitored with independent adjudication of end points.
Patients enrolled at procedure start with no mandated inclusion/exclusion criteria.
Results The ARRIVE SVG patient 2-year follow-up was 96% complete (457 of 474). The SVG patients had
signiﬁcantly more baseline comorbidities/complex disease than simple-use patients (n ⫽ 2,698) undergoing native coronary intervention or other expanded-use patients (n ⫽ 4,320 without SVG patients). They
had higher 2-year rates of mortality (10.9% vs. 4.2%, p ⬍ 0.001), myocardial infarction (5.3% vs. 2.2%,
p ⬍ 0.001), and Academic Research Consortium deﬁnite/probable stent thrombosis (4.7% vs. 1.4%, p ⬍
0.001) than the simple-use group. They also had higher 2-year adverse event rates, including signiﬁcantly
more mortality (10.9% vs. 7.5%, p ⫽ 0.008) than other expanded-use patients.
Conclusions The ARRIVE SVG patients have signiﬁcantly different baseline risk and higher clinical risk
through 2 years than simple-use and other expanded-use patients. Nonetheless, compared with historical
SVG revascularization rates, treatment with paclitaxel-eluting stent seems to offer a reasonable therapeutic option in this high-risk group. (TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multicenter Safety
Surveillance Program; NCT00569491) and (TAXUS ARRIVE 2: A Multicenter Safety Surveillance
Program; NCT00569751) (J Am Coll Cardiol Intv 2010;3:742–50) © 2010 by the American College of
Cardiology Foundation
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Saphenous vein grafts (SVG) historically have had occlusion
rates of approximately 12% to 20% after 1 year, progressing
to over 50% by 7 to 10 years (1– 4). Recently, a large
randomized controlled trial (RCT) reported per-patient
angiographic vein graft failure rates of ⬎40% by 18 months
(5). Given the higher risk of adverse outcomes associated
with repeat bypass surgery (6), percutaneous coronary intervention (PCI) is generally the preferred revascularization
option for patients with recurrent graft-related disease. In
the U.S., 6% to 10% of all PCI are performed in SVGs (7).
Patients undergoing PCI of SVG lesions with or without
bare-metal stents (BMS) also have a high risk for adverse
clinical events due to restenosis or thrombus at the treatment site and/or disease progression elsewhere in the SVG
(6,8 –12). Implantation of drug-eluting stents (DES) has
improved short- and mid-term SVG clinical outcomes
compared with BMS in some studies (13–29), but much of
the available data are retrospective. Two small prospective
RCTs have reported significantly lower angiographic restenosis with DES compared with BMS in SVGs during a
median follow-up of 18 to 32 months (30 –32).
In the absence of large RCTs of SVG stenting, registries
can provide insight into the clinical outcomes of such
patients. The ARRIVE (TAXUS Peri-Approval Registry:
A Multicenter Safety Surveillance) Program captured usage
patterns and outcomes in 7,492 patients, including 474
patients who underwent SVG stenting (33,34). With data
from the ARRIVE program, we evaluated 2-year clinical
outcomes after SVG DES implantation, compared them
with outcomes in patients receiving the same DES in
noncomplex or complex native coronary lesions, and examined outcomes in the SVG subgroup in relation to other
published studies.

Methods
Study design, data collection, and follow-up. The TAXUS

ARRIVE Program, which has been described previously,
included 2 prospective, multicenter U.S. safety surveillance registries (ARRIVE 1 [50 sites, February to May
2004] and ARRIVE 2 [53 sites, October 2004 to October
2005]) (33,34). The program was designed to enroll
consecutive patients treated with the slow-release
TAXUS Express (Boston Scientific Corporation, Natick,
Massachusetts) paclitaxel-eluting stent (PES). No specific inclusion/exclusion criteria were mandated. Patients
who gave informed consent for participation under a
protocol approved by the local institutional review board
in conformity with the Declaration of Helsinki and U.S.
Food and Drug Administration guidelines were enrolled
at the time of procedure initiation. Follow-up angiography was performed at operator discretion. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel or
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ticlopidine was begun before or immediately after the
procedure. Aspirin was continued indefinitely and thienopyridine was recommended for 6 months per the
TAXUS Express (Boston Scientific Corporation) stent
Directions For Use. At 1 year, 67.7% of ARRIVE
patients (4,687 of 6,927) were taking DAPT with 53.1%
(3,487 of 6,569) at 2 years (35). The SVG patients were
somewhat higher at 74.2% (322 of 434) and 66.6% (269
of 404), respectively. Both studies are registered (see
clinical trial registry data after abstract; identifiers
NCT00569491 and NCT00569751).
An independent clinical events committee with no financial conflicts of interest with the sponsor determined the
relationship of reported cardiac events to the study device;
an event was deemed related to the TAXUS stent if it
occurred at the stented segment
or if the relationship to the stent
Abbreviations
could not be excluded on the
and Acronyms
basis of existing information
BMS ⴝ bare-metal stent(s)
(33). Data were source verified
DAPT ⴝ dual antiplatelet
for death, major cardiac events
therapy
(cardiac death, myocardial inDES ⴝ drug-eluting stent(s)
farction [MI], target vessel reMI ⴝ myocardial infarction
vascularization [TVR], target lePCI ⴝ percutaneous
sion revascularization [TLR]
coronary intervention
[defined as “TAXUS-stentPES ⴝ paclitaxel-eluting
related” TVR]), and stent
stent(s)
thrombosis (ST) along with an
RCT ⴝ randomized
additional 10% to 20%/site rancontrolled trial
dom sampling of patients. AdjuSES ⴝ sirolimus-eluting
dication of ST per the Academic
stent
Research Consortium (ARC)
ST ⴝ stent thrombosis
definite/probable definition (36)
SVG ⴝ saphenous vein graft
was performed by an indepenTLR ⴝ target lesion
dent committee at the Harvard
revascularization
Clinical Research Institute.
TVR ⴝ target vessel
Statistical analysis. For baseline
revascularization
variables, simple proportions
were used with 2-sided p values
from a Student t test for continuous variables (summarized as mean ⫾ 1 SD) and chi-square test for discrete
variables (presented as frequencies and group percentages). Statistical analyses of events were carried out on
the basis of the clinical events committee assessment of
relation to the TAXUS stent. The Kaplan-Meier product
method (log-rank p value) was used for time-to-event
analyses. Backward Cox proportional hazards regression
was used to assess 41 variables (Appendix) to identify
predictors of major events; the threshold to remain in the
model was p ⫽ 0.10. All analyses were performed with
SAS System Software version 8.0 or higher (SAS Institute, Cary, North Carolina); p ⬍ 0.05 was considered
statistically significant.
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Results
Patient and procedural characteristics. Of 7,492 total

ARRIVE patients, 474 (6.3%) underwent stenting of an
SVG lesion (578 lesions). Most ARRIVE cases (n ⫽ 4,794)
were considered expanded-use on the basis of patient and/or
lesion characteristics outside the simple-use subgroup (n ⫽
2,698) who would have met the criteria for inclusion in the
TAXUS IV pivotal trial (37). As shown in Table 1, SVG
patients had significantly more baseline comorbidities and
complex disease than the simple-use subgroup as well as the
cohort of other expanded-use, non-SVG cases (n ⫽ 4,320).
Patients who underwent SVG stenting were mostly men
and had a high prevalence of diabetes, prior MI, and prior
PCI. Table 2 shows procedural data for the SVG subgroup.
Primary stenting was performed in approximately one-half
of SVG lesions, and an embolic protection device was used
in 29% of SVG patients at the discretion of the physician.
Clinical outcomes. Among ARRIVE SVG patients, clinical
follow-up was available in 98% (465 of 474) at 1 year and
96% (457 of 474) at 2 years. Clinical outcomes through 2
years (Kaplan-Meier analysis) in the SVG, the simple-use,
and the other expanded-use (minus SVG) cohorts are
shown in Table 3 and Figure 1. Rates for mortality, all MI,
and ST were significantly higher in the SVG subgroup than

in simple-use patients, although Q-wave MI was not.
Mortality was also significantly higher for the SVG cohort
than the subgroup of other expanded-use patients. From
year 1 to year 2, mortality increased among SVG patients
(5.1% and 5.8%, respectively), whereas MI was higher in
year 1 (3.5% and 1.8%), and ST was equal (2.4% and 2.3%).
By comparison, in the simple-use subgroup, year 1 rates
were higher for mortality (2.3% and 1.9%), MI (1.4% and
0.8%), and ST (0.9% and 0.5%). The expanded-use (minus
SVG) cohort also had higher event rates in year 1 for
mortality (4.1% and 3.4%), MI (2.5% and 1.2%), and ST
(2.2% and 1.0%). In the SVG cohort, early (0 to 30 days)
ST was 1.3% (6 of 474), and late (31 days to 1 year) ST was
1.1% (5 of 467), as reported previously (35). Among the 21
ARRIVE SVG patients suffering an ST event, 16 underwent subsequent revascularization within 30 days, all of
which were TLR. Early and late ST were 0.4% and 0.5%,
respectively, in the simple-use subgroup (35) and 1.4% and
0.8%, respectively, in the expanded-use minus SVG cohort.
In patients with SVG stenting, the 2-year rate of target
vessel failure (defined as cardiac death, MI, and TVR) was
significantly higher than in the simple-use cohort (19.9% vs.
9.6%, respectively, p ⬍ 0.001) or the subgroup of other
expanded-use patients (19.9% vs. 14.8%, p ⫽ 0.005). In the

Table 1. Comparison of Baseline Patient and Lesion Characteristics in ARRIVE Vein Graft, Simple Use, and Other Expanded Use (Minus Vein Graft) Cohorts

Variable

Vein Graft
(n ⴝ 474 Patients)
(n ⴝ 578 Lesions)

Simple Use*
(n ⴝ 2,698 Patients)
(n ⴝ 3,112 Lesions)

Other Expanded Use
(Minus Vein Graft)*
(n ⴝ 4,320 Patients)
(n ⴝ 6,874 Lesions)

p Value
Vein Graft vs.
Simple Use

p Value
Vein Graft vs.
Other Expanded Use
(Minus Vein Graft)

Patient characteristics
68.0 ⫾ 10.4 (474)

63.0 ⫾ 11.5 (2,698)

64.6 ⫾ 11.9 (4,320)

⬍0.001

⬍0.001

Male

80.8% (383)

65.9% (1,777)

66.7% (2,883)

⬍0.001

⬍0.001

Hypertension

79.7% (378)

75.4% (2,034)

75.9% (3,279)

0.04

0.06

Hyperlipidemia

88.6% (420)

74.4% (2,007)

75.2% (3,250)

⬍0.001

⬍0.001

Diabetes mellitus†

40.3% (191)

29.8% (805)

31.8% (1,372)

⬍0.001

⬍0.001

Oral medications

29.5% (140)

21.8% (589)

22.9% (989)

⬍0.001

0.001

Insulin

15.0% (71)

8.9% (241)

10.5% (452)

⬍0.001

0.003

Smoking at baseline

12.4% (59)

24.2% (652)

24.4% (1,053)

⬍0.001

⬍0.001

Age (yrs)

Prior MI

48.9% (232)

26.9% (725)

40.9% (1,765)

⬍0.001

⬍0.001

Prior PCI

48.1% (228)

34.5% (930)

36.3% (1,567)

⬍0.001

⬍0.001

Prior stroke

10.3% (49)

5.0% (135)

6.6% (283)

⬍0.001

0.002

Lesion characteristics
RVD (mm)
Lesion length (mm)
B2/C lesion
Diameter stenosis (%)
Moderate/severe calciﬁcation (%)
Restenotic lesions

3.3 ⫾ 0.5 (578)

3.0 ⫾ 0.4 (3,110)

3.0 ⫾ 0.5 (6,873)

⬍0.001

⬍0.001

16.7 ⫾ 12.6 (575)

13.7 ⫾ 5.8 (3,103)

16.4 ⫾ 10.0 (6,848)

⬍0.001

0.48

58.3% (337)

33.3% (1,035)

57.2% (3,927/6,870)

⬍0.001

0.59

86.9 ⫾ 10.1 (578)

84.4 ⫾ 10.4 (3,111)

85.7 ⫾ 11.2 (6,871)

⬍0.001

0.01

7.3% (42)

0.0% (0)

27.1% (1,863)

⬍0.001

⬍0.001

11.6% (67)

0.0% (0)

6.9% (475)

⬍0.001

⬍0.001

Data are % (n) or mean ⫾ SD (n); p values are chi-square test (binary) or t test (continuous). *Simple-use cases, with or without diabetes, excluded 1 or more of the following: acute myocardial infarction (MI);
bifurcation, cardiogenic shock, chronic total occlusion, prior brachytherapy, vein graft stenting, in-stent restenosis, large vessel (reference vessel diameter [RVD] ⬎3.75 mm), left main disease/stenting, long
lesion (⬎28 mm), moderate/severe calcification, multivessel stenting (mean of 2.1 vessels/patient), ostial lesion, renal disease (serum creatinine ⬎3.0 mg/dl or dialysis), severe tortuosity, small vessel (RVD ⬍2.5
mm). Expanded-use cases are those not described as simple-use. †Includes patients treated with diet/exercise plus those treated with oral medications and/or insulin.
ARRIVE ⫽ TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance Program; PCI ⫽ percutaneous coronary intervention.
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Table 2. ARRIVE Vein Graft Stenting Procedural Characteristics

Variable

ARRIVE Vein Graft Stenting
(474 Patients; 524 Vessels; 578 Lesions)

Clinical procedural success*

95.3% (462)

Technical success†

99.0% (483)

Implant success‡

94.4% (458)

Pre-dilation

48.3% (279)

Recipient vessel for graft§
LAD/diagonal

26.3% (152/578)

Circumﬂex/OM

38.1% (220/578)

RCA/PDA

35.5% (205/578)

Vessels treated/patient
1

89.7% (425)

2

10.1% (48)

ⱖ3

0.2% (1)

Lesions treated/patient
1

81.0% (384)

2

16.5% (78)

ⱖ3
Stents/vessel
Stents/lesion
Total stent length/lesion (mm)
Stents/patient

2.5% (12)
1.4 ⫾ 0.7 (522) (1.0, 6.0)
1.2 ⫾ 0.6 (576) (1.0, 6.0)
24.0 ⫾ 16.7 (576) (8.0, 180.0)
1.5 ⫾ 0.9 (473) (1.0, 7.0)

1

67.1% (318)

2

21.9% (104)

ⱖ3
Stent length/patient (mm)
Embolic protection device

10.8% (51)
29.3 ⫾ 21.0 (473) (8.0, 180.0)
28.9% (137)

Pre-stenting TIMI ﬂow grade (per lesion)
0

3.1% (18)

1

3.5% (20)

2

19.7% (114)

3

73.7% (426)

Post-stenting TIMI ﬂow grade (per lesion)
0

0.2% (1)

1

0.0% (0)

2

1.2% (7)

3

98.6% (569)

Post-dilation (per lesion)
Post-stent balloon pressure (atm)
Slow ﬂow/no ﬂow after PCI
Post-procedure %DS

37.9% (219)
15.9 ⫾ 4.0 (218) (3.0, 25.0)
6.6% (38)
1.3 ⫾ 6.6 (576) (0.0, 100.0)

Procedural medications储
sGPIIb/IIIa inhibitor

44.3% (210)

Bivalirudin

37.3% (177)

Aspirin

71.3% (338)

Clopidogrel

81.0% (384)

DAPT

67.7% (321)

Data are presented as % (n) or mean ⫾ SD (n) (minimum, maximum). *Clinical procedural success was defined as mean lesion diameter stenosis
⬍30%, a Thrombolysis In Myocardial Infarction (TIMI) flow grade of 3 as visually assessed by the physician, and no in-hospital clinical events
committee-adjudicated events (n ⫽ 485). †Technical success was defined as a successful delivery or deployment of the study stent to the target
lesion without device malfunction (n ⫽ 488). ‡Implant success was defined as the percentage of implant procedures exhibiting both procedural
and technical success (n ⫽ 485). §Left main in 1 patient (0.2%). 储1 patient received ticlopidine (0.2%).
DAPT ⫽ dual antiplatelet therapy (aspirin plus clopidogrel/ticlopidine); DS ⫽ diameter stenosis; LAD ⫽ left anterior descending artery;
OM ⫽ obtuse marginal; PDA ⫽ posterior descending artery; RCA ⫽ right coronary artery; other abbreviations as in Table 1.
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Table 3. Death and MI in ARRIVE Vein Graft, Simple-Use, and Other Expanded-Use (Minus Vein Graft) Cohorts

Vein Graft
(n ⴝ 474 Patients)

Simple Use*
(n ⴝ 2,698 Patients)

Other Expanded Use
(Minus Vein Graft)*
(n ⴝ 4,320 Patients)

p Value
Vein Graft vs.
Other Expanded-Use
(Minus Vein Graft)

1 yr

2 yrs

1 yr

2 yrs

1 yr

2 yrs

p Value
Vein Graft vs.
Simple-Use

Death

5.1 (24)

10.9 (50)

2.3 (60)

4.2 (108)

4.1 (173)

7.5 (303)

⬍0.001

0.008

Cardiac

3.5 (16)

7.1 (32)

1.3 (33)

2.1 (54)

2.6 (110)

4.3 (174)

⬍0.001

0.008

MI

3.5 (16)

5.3 (24)

1.4 (36)

2.2 (56)

2.5 (103)

3.7 (149)

⬍0.001

0.081

Q-wave MI

0.7 (3)

1.4 (6)

0.5 (12)

0.7 (19)

0.7 (31)

1.1 (45)

0.19

0.67

Clinical Event*

Data are from Kaplan-Meier analysis and are expressed as % (n); p values are log-rank (0 to 2 years). *Simple use and expanded use are defined in Table 1.
MI ⫽ myocardial infarction; other abbreviations as in Table 1.

SVG cohort, target vessel failure was higher in the first year
(11.9%) than during the second year (8.0%), reflecting
higher first-year rates for graft-related TVR (8.6% compared with 5.4% in year 2) (Fig. 1). Although much of the
observed graft-related TVR was driven by in-stent restenosis (5.7% in year 1, 4.5% in year 2), progressive disease in the
SVG outside the stent is a well-known failure mode for
SVG intervention, and non-TLR TVR accounted for 34%
of TVR in year 1 and 17% of TVR in year 2. In the overall
ARRIVE population, SVG stenting was an independent
predictor (1.5- to 2-fold increased risk) for death, cardiac
death, MI, TLR, and ST through 2 years (Table 4). The
increased risk for TLR was driven solely by a 2-fold
increased risk in year 2. The increased risk for ST was driven
exclusively by a 3-fold increased risk for very late ST (⬎1
year).

Discussion
The ARRIVE registries gathered data on 7,492 patients
treated in routine practice with the TAXUS Express (Boston Scientific Corporation) PES, including 474 patients
who underwent SVG stenting (33,34). These SVG patients
had significantly more comorbidities and a higher risk of
clinical events through 2-year follow-up than the subgroup
of simple-use patients (n ⫽ 2,698) who would have been
eligible for the TAXUS IV pivotal trial (37). They also had
similar or greater comorbidities and higher adverse event
rates than the cohort of other (non-SVG) expanded-use
patients (n ⫽ 4,320). However, repeat revascularization
after PES implantation in ARRIVE SVG patients (14.0%
TVR and 10.2% TLR through 2 years) was still lower than
the historical 35% to 40% failure rate of BMS in SVG at 18

Figure 1. Death/MI, ST, and Revascularization Through 2 Years in the ARRIVE Vein Graft, Simple Use, and Other Expanded-Use (Minus Vein
Graft) Subgroups
Cohorts were ARRIVE vein graft (n ⫽ 474) (red line), ARRIVE simple use (n ⫽ 2,698) (blue line), and ARRIVE other expanded use (minus vein graft, n ⫽ 4,320)
(green line). Simple use and expanded use cohorts are deﬁned in Table 1. Graft-related revascularization is shown for the saphenous vein graft (SVG) cohort.
Target lesion revascularization was deﬁned as “TAXUS-stent-related” target vessel revascularization, given the absence of a central angiographic core laboratory.
Stent thrombosis (ST) is per Academic Research Consortium (ARC) deﬁnite/probable deﬁnitions (36). The p values (log-rank) are for the comparison between vein
graft and simple use cohorts and between vein graft and other expanded use (minus vein graft) cohorts; error bars are ⫾ 1.5 SEM. MI ⫽ myocardial infarction.
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Table 4. Vein Graft Stenting as an Independent Risk Factor for Adverse
Events in ARRIVE
Event Type
(n ⴝ 7,492 ARRIVE Patients)

Hazard Ratio
(95% CI)

Death (0–2 yrs, n ⫽ 461)

1.43 (1.05–1.96)

Cardiac death (0–2 yrs, n ⫽ 260)

1.61 (1.09–2.37)

MI (0–2 yrs, n ⫽ 229)

1.86 (1.18–2.94)

TVR (0–2 yrs, n ⫽ 715)

1.60 (1.23–2.10)

TVR (0–1 yr, n ⫽ 492)

1.50 (1.07–2.11)

TVR (1–2 yrs, n ⫽ 223)

1.68 (1.12–2.53)

TLR (0–2 yrs, n ⫽ 545)

1.76 (1.30–2.39)

TLR (0–1 yr, n ⫽ 373)

NS*

TLR (1–2 yrs, n ⫽ 172)

1.77 (1.13–2.79)

ST (0–2 yrs, n ⫽ 184)

2.03 (1.27–3.23)

Early ST (0–30 days, n ⫽ 77)

NS*

Late ST (31 days–1 yr, n ⫽ 51)

NS*

Very Late ST (1–2 yrs, n ⫽ 56)

2.90 (1.44–5.83)

*p ⬎ 0.05.
ST ⫽ stent thrombosis; TLR ⫽ target lesion revascularization (TAXUS stent-related target vessel
revascularization [TVR]).

months (4,14). The ARRIVE revascularization outcomes
were similar to what was observed with PES in the
multicenter prospective SOS (Stenting Of Saphenous vein
grafts) RCT at 2 years where TVR was significantly lower
with TAXUS than with BMS (16% vs. 35%, respectively)
(32).
Long-term data have shown a reduction in TLR with DES
compared with BMS with no significant difference in death or
MI in the inherently lower-risk patients/native coronary lesions generally studied in RCTs (38). The first prospective trial
of DES in SVGs, the RRISC (Reduction of Restenosis In
Saphenous vein grafts with CYPHER sirolimus-eluting stent)
trial (n ⫽ 75), also reported a lower 6-month rate of ischemiadriven TVR for sirolimus-eluting stent (SES) compared with
BMS (5.3% vs. 27.0%, respectively, p ⫽ 0.012) as well as
reduced neointimal hyperplasia volume (30,39). However, after
a median of 32 months, the incidence of TVR was similar in
the 2 study groups due to late catch-up in the SES group (34%
for SES vs. 38% for BMS, p ⫽ 0.74) (31). Outcomes at 2 years
in ARRIVE SVG patients (14.0% TVR) are similar to that of
PES patients in SOS (16% TVR), suggesting that “real-world”
PES use in SVG lesions might have a lower revascularization
rate than BMS and potentially SES, at least through 2 years
(32,40). The ongoing BASKETSAVAGE study (Clinical
Trials Identifier, NCT00595647) will compare TAXUS with
BMS in SVG when used in conjunction with a glycoprotein
IIb/IIIa inhibitor and a distal filter system and should provide
additional randomized trial data regarding SVG stenting.
Reported revascularization rates among SVG patients
receiving DES in observational studies have been varied.
One single center study reported a 19% TVR rate at 1
year among 110 consecutive SVG patients (41). In
another single-center registry, TVR was 13% at 1 year,
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with disease progression in the nonstented segment
accounting for one-third of revascularizations (42).
Through 2 years in the STENT (Strategic Transcatheter
Evaluation of New Therapies) registry, TVR with DES
was 18.2%, similar to that in the ARRIVE program, with
a lower event rate and propensity adjusted hazard ratio
compared with BMS (7). Reports from nonrandomized
comparisons of DES and BMS in SVG lesions of various
ages have also communicated diverse results (14 –29,43,44).
Many are retrospective, and some are limited by short followup. Approximately one-half have shown some significant
revascularization benefit with DES; others have suggested no
benefit at all (45).
Late outcomes (median follow-up of 32 months) in the
RRISC trial have raised concerns about a significant albeit
not fully understood mortality excess in SVG patients
receiving SES (31). Higher mortality was not observed,
however, in the multicenter 350-patient case-control study
comparing SES with a variety of BMS in clinical use during
the 2000s (16). Through 2 years in the SOS trial, there were
numerically more deaths overall with PES versus BMS (5
vs. 2, respectively), but the BMS group had more cardiac
deaths (2 vs. 1). Annual mortality among ARRIVE SVG
patients was approximately 5.5%; although higher than in
simple-use patients, this rate was comparable to results from
2,119 patients in the Duke Cardiovascular Disease Database
where annual mortality after SVG stenting with BMS
(median follow-up of 4.8 years) ranged from 5.7% to 8.6%
(46). Among SVG patients receiving DES in the STENT
registry, mortality was 4.6% at 9 months and 8.2% at 2 years
(7). In a recently reported observational study, SVG patient
mortality through 4 years was not significantly different
between DES and BMS (22.5% vs. 27.0%, respectively, p ⫽
0.65) (28). The data overall suggest that, although DES
might not increase mortality relative to BMS, they also do
not prevent the high annual mortality rate seen in patients
after SVG stenting with BMS. Among ARRIVE SVG
patients, medically treated diabetes was a significant predictor of 2-year cardiac death (hazard ratio: 2.11, 95% confidence interval: 1.02 to 4.36, p ⫽ 0.044). Many late events
after SVG stenting are likely to reflect background disease
activity outside the stented segment, as has been reported
for lower-risk patients participating in RCTs (47,48).
Early ST was higher in the ARRIVE SVG subgroup
compared with the simple-use cohort (38), and through 2
years, ARRIVE SVG patients had a significantly higher ST
incidence (Fig. 1). Among the 21 ARRIVE SVG patients
suffering an ST event, however, all 16 revascularizations performed were TLR. Stent thrombosis could be related to
in-stent restenosis but might also result from SVG disease
progression in nonstented segments. In the overall ARRIVE
population, first-year ST reflected mostly DAPT compliance
along with anatomic and clinical factors known to increase
the risk of BMS ST, whereas ST in the second year seemed
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more related to biological markers (35). Extended DAPT use
might help reduce the high incidence of late ST, but this
remains to be proven.
Moderate, nonischemic SVG lesions have been associated
with both midterm and late cardiac events after coronary artery
bypass grafting (49 –51). Prophylactic DES stenting of such
lesions might provide preventive treatment against SVG atherosclerosis progression. In a recent report, at 1-year follow-up
the use of PES stenting of moderate nonsignificant lesions in
old SVGs compared with medical therapy alone was associated
with a lower rate of disease progression as assessed by intravascular ultrasound and a trend toward a lower cumulative
incidence of major adverse cardiac events related to the target
SVG (3% vs. 19%, respectively, p ⫽ 0.09) (52).
Study limitations. The main limitation of the current study is
its observational nature and the lack of an appropriate control
group. However, clinical outcomes in ARRIVE patients receiving a PES in a vein graft were similar to those of the PES
arm of the SOS trial. To be in the ARRIVE registry, a patient
had to receive a TAXUS Express stent, and this operator
choice might have been influenced by the angiographic appearance of the lesion and the clinical characteristics of the
patient. The incidence of MI might be underestimated, because systematic measurement of cardiac biomarkers was not
mandated by the study protocol. The comparatively low (29%)
use of embolic protection in this series is consistent with the
low penetration of this group of technologies, despite numerous trials showing reduction in adverse events when embolic
protection is used during SVG intervention (53). The angiographic data were based on visual assessment at each site and
were not evaluated by an independent core laboratory. The MI
rates reported in the article represent clinical MI, but the rates
of peri-procedural MI were not collected.
Conclusions
The ARRIVE patients undergoing SVG stenting have
more baseline comorbidities and higher risk for adverse
events compared with patients undergoing simple native
coronary artery stenting and even those undergoing complex
(non-SVG) stenting. Although the 2-year repeat revascularization rates in SVG patients are higher than in simpleuse patients, they are lower than historical revascularization
rates for BMS in SVGs. Outcomes in the ARRIVE SVG
group are similar to that of the PES arm in the SOS trial
and suggest that use of the TAXUS Express stent might
have a lower repeat revascularization rate than when BMS
are used to treat focal SVG disease. These results provide
further support for a large, prospective, multicenter RCT of
DES in SVG lesions (45,54).
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Appendix
Baseline Characteristic Variables Used in
Predictor Modeling

Acute MI
Age ⬎70 yrs
Bifurcation
Brachytherapy, prior
CABG, previous
Cardiogenic shock
Chronic total occlusion
Congestive heart failure (site reported as
NYHA functional class ⱖIII)
Diabetes, insulin treated
Diabetes, not requiring insulin
Gender, male
Hypercholesterolemia (patient was
reported as having this condition and
may or may not have been receiving
medication for it)
Hypertension (patient was reported as
having this condition and may or may
not have been receiving medication
for it)
In-stent restenosis
IVUS post deployment
IVUS pre-deployment
LAD as target vessel
Left main disease

Left main stenting
Lesion ⬎28 mm
Lesion calciﬁcation (moderate and
severe)
Lesion type B2/C
MI, previous
Multiple overlapping stents
Multiple stents per patient
Multivessel disease
Multivessel stenting
Ostial lesion
PCI, previous
Post-procedure dilation
Pre-procedure dilation
Pre-procedure TIMI ﬂow grade 0
Renal disease (Site reported as serum
creatinine ⬎3.0 mg/dl or patient
on dialysis)
RVD ⬍3 mm
Smoking at baseline
Stent inﬂation pressure ⬎14 atm
Stroke, previous
Thienopyridine ⬍12 months
Thienopyridine ⬍6 months
Tortuosity, severe
Vein graft

Hazard ratios were assessed with the Cox proportional hazards regression model; backward
selection was used; the threshold to stay in the model was set at 0.10.
CABG ⫽ coronary artery bypass graft; IVUS ⫽ intravascular ultrasound; LAD ⫽ left anterior
descending artery; MI ⫽ myocardial infarction; PCI ⫽ percutaneous coronary intervention; RVD ⫽
reference vessel diameter; TIMI ⫽ Thrombolysis In Myocardial Infarction.
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